{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:57:03Z","timestamp":1765976223711,"version":"3.48.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian Pediatr"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13312-025-00221-3","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:25:05Z","timestamp":1763540705000},"page":"40-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Infliximab in Infantile Kawasaki Disease: Experiences over 8 Years"],"prefix":"10.1007","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6272-9069","authenticated-orcid":false,"given":"C. Ravali Pratima","family":"Goud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhea","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anindita","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigna N.","family":"Bathia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3273-6218","authenticated-orcid":false,"given":"Priyankar","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"221_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4070\/kcj.2018.0214","volume":"49","author":"G Hur","year":"2019","unstructured":"Hur G, Song MS, Sohn S, et al. Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: a multicenter study in Korea. Korean Circ J. 2019;49:183\u201391.","journal-title":"Korean Circ J"},{"key":"221_CR2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3341","volume":"143","author":"A Dionne","year":"2019","unstructured":"Dionne A, Burns JC, Dahdah N, et al. Treatment intensification in patients with Kawasaki disease and coronary aneurysm at diagnosis. Pediatrics. 2019;143:e20183341.","journal-title":"Pediatrics"},{"key":"221_CR3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1136\/archdischild-2023-325639","volume":"108","author":"K Miyata","year":"2023","unstructured":"Miyata K, Bainto EV, Sun X, et al. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis. Arch Dis Child. 2023;108:833\u20138.","journal-title":"Arch Dis Child"},{"key":"221_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1097\/INF.0000000000001951","volume":"37","author":"PN Jone","year":"2018","unstructured":"Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glod\u00e9 MP, Dominguez SR. Infliximab plus intravenous immunoglobulin (IVIG) versus IVIG alone as initial therapy in children with Kawasaki disease presenting with coronary artery lesions: is dual therapy more effective? Pediatr Infect Dis J. 2018;37:976\u201380.","journal-title":"Pediatr Infect Dis J"},{"key":"221_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s13312-020-2033-1","volume":"57","author":"B Shenoy","year":"2020","unstructured":"Shenoy B, Singh S, Ahmed MZ, et al. Indian academy of pediatrics position paper on Kawasaki disease. Indian Pediatr. 2020;57:1040\u20138.","journal-title":"Indian Pediatr"},{"key":"221_CR6","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s40262-018-0653-6","volume":"57","author":"N Vande Casteele","year":"2018","unstructured":"Vande Casteele N, Oyamada J, Shimizu C, et al. Infliximab pharmacokinetics are influenced by intravenous immunoglobulin administration in patients with Kawasaki disease. Clin Pharmacokinet. 2018;57:1593\u2013601.","journal-title":"Clin Pharmacokinet"},{"key":"221_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/INF.0000000000002503","volume":"39","author":"M Miura","year":"2020","unstructured":"Miura M, Kobayashi T, Igarashi T, et al. Real-world safety and effectiveness of infliximab in pediatric patients with acute Kawasaki disease: a postmarketing surveillance in Japan (SAKURA study). Pediatr Infect Dis J. 2020;39:41\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"221_CR8","first-page":"S134","volume":"34","author":"S Singh","year":"2016","unstructured":"Singh S, Sharma D, Suri D, Gupta A, Rawat A, Rohit MK. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India. Clin Exp Rheumatol. 2016;34:S134\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"221_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S2352-4642(21)00270-4","volume":"5","author":"JC Burns","year":"2021","unstructured":"Burns JC, Roberts SC, Tremoulet AH, et al. KIDCARE Multicenter Study Group. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021;5:852\u201361.","journal-title":"Lancet Child Adolesc Health"},{"key":"221_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002677","volume":"39","author":"T Furuta","year":"2020","unstructured":"Furuta T, Yasudo H, Ohnishi Y, et al. The efficacy and safety of infliximab therapy for refractory Kawasaki disease in infants. Pediatr Infect Dis J. 2020;39:e219.","journal-title":"Pediatr Infect Dis J"}],"container-title":["Indian Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-025-00221-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13312-025-00221-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13312-025-00221-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:47:47Z","timestamp":1765975667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13312-025-00221-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["221"],"URL":"https:\/\/doi.org\/10.1007\/s13312-025-00221-3","relation":{},"ISSN":["0019-6061","0974-7559"],"issn-type":[{"type":"print","value":"0019-6061"},{"type":"electronic","value":"0974-7559"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Ethics Committee, Institute of Child Health; Ref No: IEC\/222\/2020, dated Jan 20, 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}